Maria Vilenchik, Ph.D.
CEO and Founder
Dr. Maria Vilenchik formed Felicitex Therapeutics in 2012. Prior to that Dr. Vilenchik led Drug Discovery programs at Hoffman-La Roche and Memorial Sloan Kettering Cancer Center. She authored 20 publications in peer reviewed journals and 8 patents. Maria received M.S. in Biophysics from Brandeis University and Ph.D. degree in Pharmacology from Columbia University.
Michael Frid, Ph.D.
Head of Preclinical
Dr. Michael Frid brings years of pharmaceutical industry experience, perspective to bear, and experience collaborating with a broad array of biopharmaceutical companies. Dr. Frid is an organic chemist and is an expert in drug discovery and early drug development. He received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT) working with Professor S. L. Buchwald.
Marc Duey, MBA
Chairman of the Board
With over two decades of experience in the Pharmaceutical and Biotechnology fields, Marc Duey brings a great deal of background and experience to his role as President and CEO of ProMetrics, Inc. Under his direction, the firm has serviced over 100 clients and managed over 5,000 projects.
Mr. Duey is a member of numerous trade and industry associations and sits on the Board of Directors of several technology companies. He is an adjunct professor at the business school (MBA) as well as an adjunct professor for the Pharmaceutical Product Development program at West Chester University in West Chester, Pennsylvania.
Scientific Advisory and Board of Directors
Neal Rosen, MD, Ph.D.
Dr. Rosen is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School. His major interests are the identification and study of key molecular events and growth signaling pathways responsible for the development of human cancer and the use of this information for developing mechanism-based therapeutic strategies.
He has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and pioneered the concept that cancer cells are dependent on cellular machinery for protein folding. Multiple novel clinical trials based on the work of the Rosen laboratory are being tested at Memorial Sloan-Kettering and other cancer centers in the United States and internationally.
Dr. Rosen received his undergraduate degree in Chemistry from Columbia College and an M.D., Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women’s Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer Institute. He was on the senior staff of the Medicine Branch at the NCI prior to joining the faculty of Memorial Sloan-Kettering Cancer Center.
Yuriy Gankin, Ph.D., Founder
Yuriy Gankin has a background in business development, chemo and bio-informatics and over 20 years of experience working with global pharmaceutical companies in the realm of scientific informatics. He now serves as Chief Life Sciences Officer and Vice President of the Life Sciences Business Unit at EPAM Systems Inc. following the acquisition of GGA Software Services LLC and Institute of Theoretical Chemistry, Inc. by EPAM in June 2014. As a co-founder of GGA and ITC, he helped build GGA and ITC into the leading Russian provider of scientific software engineering, algorithm development, and data curation services for the life sciences industry.
Prior to founding GGA and ITC Yuriy has worked at a global scientific publishing company Elsevier MDL as a director of content database development. Yuriy has a background in research, database development, and modeling in chemistry, material science, and biology. Yuriy graduated with a M.S. degree in physical chemistry from St. Petersburg Chemical Technology University and received his Ph.D. degree in analytical chemistry from Tufts University in 1996.
Valeria Povolotsky, Ph.D.
Valeria has 25 years experience in Biotech and Pharma Industry, being involved in Drug Development for over 15 years, and over 10 years in the Global Business and Partnering. Currently, she serves as a member of the board at Brazilian company PharmaPraxis, US company Cure Lab, US company Felicitex Therapeutics, VP Global Partnering at Russian Pharmaceutical company R-Pharm.Valeria has Ph.D. in Clinical Pharmacology and M.S. in Biological Chemistry.
Alex Shlyankevich, Ph.D.
Alex has 25 years of leadership experience in pharmaceutics at a number of start ups and established companies, including Cardinal Health, Biovail, CombinatoRx, Avecia and Moderna. In his current role, Alex is managing portfolio of healthcare investment projects and serves on the boards of NuPulseCV (USA) and GiviVision (UK).
© 2019 by Felicitex Therapeutics, Inc »« 27 Strathmore Road Natick, MA 01760 1-919-213-0025 (p) Click here to Contact Us!